Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors

International Immunopharmacology

Volumn 1, Issue 1, 2001, Pages 105-118

  Kiener, Peter A ^a   Davis, Patricia M ^a   Murray, Judy L ^a   Youssef, Sonia ^a   Rankin, Bruce M ^a   Kowala, Mark ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cytokine; HMG CoA reductase; Inflammation; Leukocyte; Monocyte

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; MEVALONIC ACID; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; INFLAMMATION; LEUKOCYTE; LIPOPHILICITY; MALE; MONOCYTE; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL LINE; CHEMOKINE CCL2; CHOLESTEROL; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-8; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; PRAVASTATIN; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035129882     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00272-1     Document Type: Article

References (55)

1. Oxidized lipoproteins influence gene expression by causing oxidative stress and activating the transcription factor NF-kappa B
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
4. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
5. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors
6. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
7. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia
8. Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages
9. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras
10. Regulation of the mevalonate pathway
11. Rab11a is modified in vivo by isoprenoid geranylgeranyl
12. 3-Hydroxy-3methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
13. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
14. Inflammatory mechanisms of atheroma formation. Influence of fluid mechanics and lipid-derived inflammatory mediators
15. Human monocytic cells contain high levels of intracellular Fas ligand: Rapid release following cellular activation
16. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human iymphocytes in vitro
17. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo
18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
19. Molecular determinants of atherosclerotic plaque vulnerability
20. Cytokines and growth regulatory molecules in atherosclerosis
21. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors
22. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
23. Effects of lovastatin on natural killer cell function and other immunological parameters in man
24. HMG-CoA reductase inhibitors in organ transplantation
25. Effects of lovastatin on the immune system
26. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
27. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
28. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
29. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats
30. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
31. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
32. Inhibition of pro-inflammatory cytokine production by pravastatin
33. The pathogenesis of atherosclerosis: Perspective for the 1990s
34. Atherosclerosis - An inflammatory disease
35. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation
36. Systemic immune reactions to HMG-CoA reductase inhibitors
37. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
38. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells
39. Effect of statins on C-reactive protein in patients with coronary artery disease
40. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release
41. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells
42. The Scandinavian Simvastatin Survival Study, randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S)
43. Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells
44. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis
45. Do calcium channel blockers and HMG-CoA reductase inhibitors attenuate allograft arteriopathy?
46. HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: Evidence for antigen-independent mechanisms?
47. Rho GTPases and signaling networks
48. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types
49. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans - In vitro and in vivo studies
50. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
51. Lovastatin induces differentiation of Mono Mac 6 cells
52. The continuing challenge of cardiac transplant arteriosclerosis
53. Modulation of human hepatocyte acute phase protein production in vitro by n - 3 and n - 6 polyunsaturated fatty acids
54. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
55. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatinlactone